Safety and efficacy of switching to bictegravir–lenacapavir versus continuing bictegravir–emtricitabine–tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial Eric G Meissner, MDa Send email to meissner@musc.edu ∙ Prof Moti Ramgopal, MDb ∙ Peter J Ruane, MDc ∙ William Sanchez, MDd ∙ Gordon Crofoot, MDe ∙ Jean-Pierre Routy, MDf ∙ et al.

Safety and efficacy of switching to bictegravir–lenacapavir versus continuing bictegravir–emtricitabine–tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial Eric G Meissner, MDa Send email to meissner@musc.edu ∙ Prof Moti Ramgopal, MDb ∙ Peter J Ruane, MDc ∙ William Sanchez, MDd ∙ Gordon Crofoot, MDe ∙ Jean-Pierre Routy, MDf ∙ et al. https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(26)00078-0/abstract?dgcid=raven_jbs_etoc_feature_lanhiv